Anthrax vaccines: past, present and future

Vaccine

Volumn 9, Issue 8, 1991, Pages 533-539

  Turnbull, Peter C B ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; NONHUMAN; REVIEW; VACCINATION;

ANIMAL; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL VACCINES; GREAT BRITAIN; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; SPORES, BACTERIAL; UNITED STATES; USSR; VACCINES, ATTENUATED;

EID: 0025868227     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(91)90237-Z     Document Type: Review

References (56)

1. De l'atténuation des virus et de leur retour à la virulence
2. Méthode pour prévenir la rage apràs morsure
3. Anthrax
4. Lectures on some recent investigations into the pathology of infectious and contagious diseases
5. Quotation in Notes, Comments, and Answers to Correspondents
6. Anthrax
7. The use of saponin spore vaccine for inoculation against anthrax in South Africa
8. The effect of large scale active immunization against anthrax
9. The effects of different carbon dioxide concentrations on the growth of virulent anthrax strains
10. The immunization of laboratory animals against anthrax
11. The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis
12. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig
13. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity
14. −) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen
15. Differences in susceptibility of inbred mice to Bacillus anthracis
16. Anthrax (Siberian plague)
17. Studies on immunity in anthrax
18. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures
19. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity
20. Field evaluation of a human anthrax vaccine
21. Immunization studies with attenuated strains of Bacillus anthracis
22. Recent advances in the development of an improved human anthrax vaccine
23. Thoroughly modern anthrax
24. Purification of factor I and recognition of a third factor of the anthrax toxin
25. The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity
26. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells
27. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells
28. Production and purification of anthrax toxin
29. Anthrax toxin
30. Purification of anthrax toxin components by high performance anion exchange, gel-filtration and hydrophobic interaction chromatography
31. Protection conferred by microbially-supplemented UK and purified PA vaccines
32. Evidence for plasmid-mediated toxin production in Bacillus anthracis
33. Plasmids, Pasteur, and anthrax
34. The genetic basis of Pasteur's attenuation of Bacillus anthracis
35. Plasmids of Bacillus anthracis
36. Cloned protective activity and progress in development of improved anthrax vaccines
37. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis
38. Protective efficacy of anthrax vaccines against aerosol challenge
39. The effect of inflammation on the development of immunity to anthrax in guinea pigs
40. Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants
41. Transposon Tn 916 mutagenesis in Bacillus anthracis
42. Proteolytic activation of anthrax toxin bound to cellular receptors
43. A model for anthrax toxin action at the cellular level
44. Analyses of Bacillus anthracis vegetative cell surface antigens and of serum protease cleavage of protective antigen
45. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo
46. Role of epidemiology in vaccine policy
47. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form 1 antigen genes into the galE Salmonella typhi Ty 21a typhoid vaccine strain
48. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine
49. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas
50. Enteroadhesion fimbriae and enterotoxin of Escherichia coli: genetic transfer to a streptomycin-resistant mutant of galE oral-route live-vaccine Salmonella typhi Ty21a
51. Immunogenicity of Ty21a expressing O-polysaccharide antigen of Vibrio cholerae
52. Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin
53. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier
54. Anthrax in the UK
55. Anthrax vaccine development: a continuing story